ViractaTrader77 Posted - 3 days ago

Flipper shelf funds must be out by now. That’s what drove it down plus interest rates and market. But this management team was smart they have tons of cash with Point72 and Ispen Pharma They $STRO has the same partnering business model that Immunogen had in antibody drug conjugates and same lead asset that got them acquired for $10 billion. There were 3+ big pharma players looking to acquire Immunogen and Abbvie won. I think this will get acquired for $13-24 a share this summer. $IMGN and same lead asset as Profound Bio. This is a perfect hedged opportunity (turnkey) for a big pharma to buy to grab the asset, cash and partnerships in the hottest niche in biotech. $VKTX

GPS_OS_21_vs_SOC_5 Posted - 5 days ago

$SLS Elahere $IMGN was bought for $10.1B after achieving 16.46 months of median Overall Survival for Platinum Resistant Ovarian Cancer patients. Gps + Keytruda achieved Os of 18.4 Months in the same setting. $MRK Keytruda alone was 13 months. https://www.elahere.com/results-with-elahere#overall-survival

GPS_OS_21_vs_SOC_5 Posted - 6 days ago

@jacksparo Unblinded p3 results Imminent / idmc meeting this month, offers an investment opportunity of a lifetime. - all pooled p3 patients, Gps and Bat combined have an os of 16 months - Fda only requires Gps os of 12.6 for approval / its closer to 24 - 25 doctors treating regal patients state, bat os is only 6 months or 6-8 months - Gps achieved a highly statistically significant os of 21 months in the p2 Fact: the last time we were awaiting an idmc update the share price climbed 300% in advance - contemporaneous aml 2nd remission trial data is in from md anderson w 6.5 months of os - gps has increased os 2, 3, 4x in a total of 11 trials - Increased os has been directly correlated w Gps immunotherapy immune responses. $Imgn was a $270m co when it released it p3 data - bought for 10b - Cpxx was a $50m co when it released its p3 aml data, bought for $1.5b 60 days later. - Gps is worth 100x + the current share price ... w an emphasis on the + and the whole ’market’ is about to find out.

GPS_OS_21_vs_SOC_5 Posted - 6 days ago

$SLS Unblinded p3 results Imminent / idmc meeting this month, offers an investment opportunity of a lifetime. - all pooled p3 patients, Gps and Bat combined have an os of 16 months - Fda only requires Gps os of 12.6 for approval / its closer to 24 - 25 doctors treating regal patients state, bat os is only 6 months or 6-8 months - Gps achieved a highly statistically significant os of 21 months in the p2 Fact: the last time we were awaiting an idmc update the share price climbed 300% in advance - contemporaneous aml 2nd remission trial data is in from md anderson w 6.5 months of os - gps has increased os 2, 3, 4x in a total of 11 trials - Increased os has been directly correlated w Gps immunotherapy immune responses. $Imgn was a $270m co when it released it p3 data - bought for 10b - Cpxx was a $50m co when it released its p3 aml data, bought for $1.5b 60 days later. - Gps is worth 100x + the current share price ... w an emphasis on the + and the whole ’market’ is about to find out.

zambono Posted - 1 week ago

@moonbear nice, it went from $4 to $31 within the year $IMGN . People are inpatient, $TPST was 30 cents not too long ago.

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

@OnTheBalance All the Variables and Facts Stack up to a large number of billions: Patent locked down on all Key WT1+ Epitopes - the only true targetable OncoGene for AML - ie once its knocked out, its dead, there is no Mutational burden. Gos Expiry 2035 + orphan + Gps+ restarts the Clock Market Scope for AML 10K 2nd Remission, 15k 1st + Est 75K now in remission right now... CCo published pricing comps starting at $260k Per Patient Per year $2.6B for Cr2 - $3.5B for CR1 + Post ASCT + Additional WT1 Targets. $IMGN Got bought for 10B just for its FRA+ Ovarian Cancer Results, WT1 + OC is bigger and GPs OS is Better. I do not see the board / Ceo Selling for less than $10B or Appx $97 Per Share ALL IN - Includes all Shares. - Then add in 009.

ViractaTrader77 Posted - 1 week ago

No brainer acquisition for a big pharma for a billion dollars in equity for Sutro Biopharma. Nextgen $IMGN adc which was cornerstone of $ABBV deal- drug similar warhead. Tons of partnership money flowing in from Astellas and Ispen Pharma. Treasure trove of cash… this won’t last long….$STRO $GMAB just paid $1.8 billion for similar drug… easy 4x upside

GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS @Wut_About_Bob as a matter of fact in the Ph2 Gps Keytruda $MRK published abstract trial for advanced, platinum resistant/refractroy ovarain cancer patients, the Memorial Sloan Kettering and Merck Doctors said Gps immunotherapy was directly correlated to increased survival, (13 months w Key alone vs 18.4 w Gps - obviously they see Gps working) and Gps would work even better in a Remission maintenance setting - like the current P3, imminently due P3. note: elahere was approved in this same setting proc w 16.4 months of os, $IMGN and got bought for 10.1b. $MRK / $BMY will be paying a premium for a deRisked Gps once the P3 is In, any day now.

ViractaTrader77 Posted - 1 week ago

$IMGN $AMAM $VKTX $PYXS Trading beneath cash, tons of big pharma partnerships. 2 folate ADCs acquired in past 18 mos for $12 billion combined. Could be next major adc acquisition target. Do your homework on Sutro https://x.com/BiotechTVHQ/status/1775900116924448891

Ridiculous78 Posted - 2 weeks ago

$ALPN Price action is always telling to a buyout.. Writing was on the wall over at $AMAM and $IMGN as well! $JANX could be next 🤔

FE123 Posted - 2 weeks ago

$IOVA $IMGN Many Similarities, FDA approvals, outstanding shares and now price Pattern! $IMGN after approval went up to $21 back down to $13 and then Buyout for $32 Would definitely like to see $IOVA have more of a Higher Buyout like $IMMU at $88, but we shall see!

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

@bikechain $97 is a 10b ALL IN, Buyout. $IMGN was bought for 10.1B based on Elahere achieving 16.46 months of OS for PROC and Approval. GPs +$mrk achieved 18.4 in the same setting. Just Ovarian cancer is worth 10B.

ViractaTrader77 Posted - 2 weeks ago

HC wainwright predicts better efficacy for Sutro $STRO than the drug $ABBV just bought for $10.8 billion from $IMGN and Sutro trading at cash value. Major upside potential. $ADCT

ViractaTrader77 Posted - 2 weeks ago

$AMAM $IMGN $LVTX

ViractaTrader77 Posted - 2 weeks ago

$STRO who will end up acquiring Sutro (astellas partnered with both ambrx and Sutro and JNJ just bought them for $2 bil) Ispen Pharma or astellas??. Sutro trading beneath cash and they have 1.6 million shares of Vaxcyte. Both very large pharmaceutical companies. Ispen just infused $25 million investment in Sutro’s stock and upon milestone putting in another $10 million. And they acquired the adc for $50 million upfront+ 800 mil in milestones. Since Abbvie acquired $IMGN for $10 billion their might be a white knight like astellas that comes in and buys Sutro for their Ovarian ADC. Astellas already gave Sutro $90 million. $PYXS $IOVA $IBRX

GPS_OS_21_vs_SOC_5 Posted - 3 weeks ago

@BigSal69 $SLS -- there are nearly 50 institutional funds currently, with some shares, that are going to be doing the following math, when the P3 confirms Gps efficacy: 10,000 AML CR2 Patients First Fda Approved Indication at $260K per patient, $2.6B TAM - estimated Patient Uptake 70% 75,000 Current AML remission and Post Allo Stem Cell transplant ... all who will benefit from Gps Immunotherapy Compare that - to the current $60m MCAP. 15,000 AML CR1 Patients - Expanded Label 12,000 Platinum Resistant Ovarian cancer 3,000 Mesothelioma $IMGN just got bought for 10.1b based on Elahere P3 OS data of 16 months, Gps + Keytruda is at 18.4 - in a less healthy setting. Massive Upside right now. and the results are Imminently Due.

GPS_OS_21_vs_SOC_5 Posted - 3 weeks ago

$SLS Price will be climbing every day we wait for the Imminently Due P3 announcement ... and then its lift off ... What is an Immunotherapy that will treat 25,000 AML remission patients worth? -- Its the question the 'market' will be considering. -- Cco published analog pricing comps of $260K minimum -- 260K * 25,000 Just AML maintenance is a $6B TAM for this $64M of short Manipulated Equity Gps achieving statistical efficacy in this firs AML Remission, patient setting then opens the door for many other indications. We already have PH2 Published Gps Keytruda $MRK combination Ovarian Cancer data better (18.4 months of OS ) than a Elahere $IMGN (16.46 Months)that got bought for 10B. Then look at these Gps + Opdivo $BMY Mesothelioma results + 3,000 More Patients. - https://www.asbestos.com/news/2024/01/31/early-vaccine-shows-promise/

Pbake87 Posted - 3 weeks ago

$XFOR check out $IMGN stock. when they announced the stock inducement award in 2023 Jan 4, the sp blew through the roof. Check it out. this was just announced here AH. $AKBA $ICU

ViractaTrader77 Posted - 3 weeks ago

Trading at cash with $IMGN and $IMNM type ADC’s. Easy double in Sutro Biopharma from here. $STRO

FE123 Posted - 03/29/24

$IOVA this is where $IMGN price was when Buyout was announced for $32 but leaning towards $IMMU price of $88 by year end!

ViractaTrader77 Posted - 03/28/24

$STRO has no enterprise value. Could triple from here. Has Ror-1 like $IMNM and they are at $1.5 billion market cap. And seeking alpha says there drug is better than $IMGN

FE123 Posted - 03/25/24

$IOVA If $IMGN was purchased for $32 we are Worth over $50!!

NEWBIGTECH Posted - 4 weeks ago

$IMGN $BMY $MRK $SLS

DGANG3 Posted - 1 month ago

$IMGN Cashed in and bought IOVA but this company, IMGN, sold their souls and could have been collecting $60-80/sh if they waited 6-8 months for this announcement and sales info like everyone wanted when the sale was announced. I wonder if Eunady has a big job at Abbvie? Sad

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$IMGN $BMY $MRK $SLS You can Easily See why BMY and MRK will Be in a bidding war for Gps.

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$IMGN $BMY $MRK $SLS https://www.asbestos.com/news/2024/01/31/early-vaccine-shows-promise/

JakeDelToro Posted - 1 month ago

$IMGN $BMY $MRK $SLS

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS Gps + Keytruda Median OS of 18.4 Months for Platinum Resistant Ovarian Cancer patients, Dire, end stage Setting. - Compare GPs + Key $MRK 18.4 Months of Overall Survival to 16.46 w Elahere for $IMGN $10.1B Buyout as a result of this P3 - Compare 18.4 to SOC, and to Keytruda Stand alone at 13.8. - This Helps to explain why $MRK and $BMY will be bidding against Each other. The audio File and Accompanying SLIDE Deck is very informative / Again Confirms GPS IMMUNOTHERAPY WORKS https://cslide.ctimeetingtech.com/igcs23/attendee/eposter/poster/363

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS 81.05% of Every Share Sold on Friday was Sold Short, on the Down Tick -- Manipulated SHARE PRICE - Over Shorted. -- Now that SLS just raised Cash with Registered Direct Offering, and prioritized Commercial Partnerships -- There will be no Offerings this Time to Save these Scumbags when the P3 Data Hits and Drops a House on them. Phase 3 Data is incoming - Its COMING. Its Due in Q1. - a Positive P3 Result, will GPS Immunotherapy the FDA green light to treat 25,000 AML Remission patients, and Generate Upwards of $6B Per yer. This $57M of Short Manipulated Equity is about to be worth $5B and Climbing. Just one Comp $IMGN got bought for 10.1B based on its PROC p3 result of 16.46 months of OS - Gps + Keytruda achieved 18.4 months in the. same. exact. setting.

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS Gap up at the Open to $14 or $15 on Tuesday - $750M Mcap and it'll Keep Running. $IMGN Bought for $10.1B Just got FDA Approval Today for ELAHERE which Achieved an OS of 16.46 months for PROC / GPS + Keytruda $MRK achieved OS of 18.4 months in the same Setting. $XBI